NasdaqCM:ATHX

Stock Analysis Report

Executive Summary

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Athersys's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATHX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-27.6%

ATHX

3.5%

US Biotechs

2.4%

US Market


1 Year Return

97.3%

ATHX

4.6%

US Biotechs

-10.0%

US Market

Return vs Industry: ATHX exceeded the US Biotechs industry which returned -1.1% over the past year.

Return vs Market: ATHX exceeded the US Market which returned -15.9% over the past year.


Shareholder returns

ATHXIndustryMarket
7 Day-27.6%3.5%2.4%
30 Day104.3%-3.2%-11.0%
90 Day140.0%-2.4%-19.4%
1 Year97.3%97.3%5.4%4.6%-8.1%-10.0%
3 Year100.0%100.0%19.3%16.3%17.3%9.6%
5 Year9.5%9.5%-4.4%-8.9%36.1%21.1%

Price Volatility Vs. Market

How volatile is Athersys's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Athersys undervalued compared to its fair value and its price relative to the market?

19.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATHX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ATHX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATHX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATHX is overvalued based on its PB Ratio (19.4x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Athersys forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATHX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATHX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATHX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATHX's revenue is expected to decline over the next 3 years (-116% per year).

High Growth Revenue: ATHX's revenue is forecast to decline over the next 3 years (-116% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATHX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Athersys performed over the past 5 years?

-20.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATHX is currently unprofitable.

Growing Profit Margin: ATHX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATHX is unprofitable, and losses have increased over the past 5 years at a rate of -20.4% per year.

Accelerating Growth: Unable to compare ATHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: ATHX has a negative Return on Equity (-191.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is Athersys's financial position?


Financial Position Analysis

Short Term Liabilities: ATHX's short term assets ($37.2M) exceed its short term liabilities ($12.8M).

Long Term Liabilities: ATHX's short term assets ($37.2M) exceed its long term liabilities ($5.6M).


Debt to Equity History and Analysis

Debt Level: ATHX is debt free.

Reducing Debt: ATHX has no debt compared to 5 years ago when its debt to equity ratio was 0.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATHX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ATHX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4% each year


Next Steps

Dividend

What is Athersys's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ATHX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATHX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATHX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATHX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Gil Van Bokkelen (58yo)

24.5s

Tenure

US$1,701,622

Compensation

Dr. Gil Van Bokkelen, Ph.D. serves as an Investment Advisor to Early Stage Partners, a venture capital fund based in Ohio. Dr. Van Bokkelen co-founded Athersys, Inc. in October 1995 and has been its Chief  ...


CEO Compensation Analysis

Compensation vs Market: Gil's total compensation ($USD1.70M) is about average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Gil's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Gil Van Bokkelen
Co-Founder24.5yrsUS$1.70m0.92% $4.4m
William B. Lehmann
President13.83yrsUS$1.14m0.13% $637.3k
John Harrington
Co-Founder24.5yrsUS$1.13m0.28% $1.4m
Laura Campbell
Principal Accounting Officer0.25yrUS$677.65k0.15% $720.2k
Ivor Macleod
Chief Financial Officer0.25yrno datano data
Karen Hunady
Director of Corporate Communications & Investor Relationsno datano datano data
Manal Morsy
Senior VP & Head of Global Regulatory Affairs7.25yrsno datano data
Robert Mays
VP of Regenerative Medicine & Head of Neuroscience Programs3.75yrsno datano data
Anthony Ting
VP of Regenerative Medicine & Head of Cardiopulmonary Programs3.75yrsno datano data
Rakesh Ramachandran
Head of Information Technology & Communications and VP3.25yrsno datano data

3.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ATHX's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gil Van Bokkelen
Co-Founder24.5yrsUS$1.70m0.92% $4.4m
John Harrington
Co-Founder24.5yrsUS$1.13m0.28% $1.4m
Lorin Randall
Independent Director12.58yrsUS$153.55kno data
C. Caskey
Scientific and Clinical Advisorno datano datano data
James Shook
Scientific and Clinical Advisorno datano datano data
Lee Babiss
Lead Independent Director6.5yrsUS$160.05kno data
Ira Mellman
Scientific and Clinical Advisorno datano datano data
Catherine Verfaillie
Scientific and Clinical Advisorno datano datano data
Michael Simons
Scientific and Clinical Advisorno datano datano data
Gilbert Clincke
Scientific and Clinical Advisorno datano datano data

16.1yrs

Average Tenure

69yo

Average Age

Experienced Board: ATHX's board of directors are seasoned and experienced ( 16.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATHX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11%.


Top Shareholders

Company Information

Athersys, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Athersys, Inc.
  • Ticker: ATHX
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$477.588m
  • Shares outstanding: 165.83m
  • Website: https://www.athersys.com

Number of Employees


Location

  • Athersys, Inc.
  • 3201 Carnegie Avenue
  • Cleveland
  • Ohio
  • 44115
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATHXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2007
4LSDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2007
4LSBRSE (Berne Stock Exchange)YesCommon StockCHCHFJun 2007

Biography

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 09:43
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.